Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis
Cattaneo, M.; Tenconi, P.M.; Alberca, I.; Garcia, V.V.; Mannucci, P.M.
Thrombosis and Haemostasis 64(3): 358-360
1990
ISSN/ISBN: 0340-6245 PMID: 2096487 Document Number: 364123
The intravenous infusion of 1-deamino-8-D-arginine vasopressin (DDAVP) shortens the prolonged bleeding time in patients with congenital or acquired bleeding disorders, including patients with uremia or liver cirrhosis. We carried out a double-blind, placebo-controlled crossover study in ten patients with liver cirrhosis to evaluate whether or not their prolonged bleeding times could be shortened by subcutaneous injections of DDAVP (0.3 microgram/kg), a more practical route of administration than intravenous infusions. One hour after DDAVP injection the bleeding time was significantly shortened (p less than 0.05). After 4 h, however, the bleeding time shortening was no longer statistically significant. There was no bleeding time change after placebo. Plasma levels of von Willebrand factor antigen (vWF:Ag) did not significantly increase after DDAVP or placebo. The study shows that subcutaneous DDAVP is an alternative method for short-term shortening of the bleeding time in liver cirrhosis.